{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040590","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.893281+00:00","generated_at":"2026-06-11T21:46:11.677234+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Assembly Bio Q2 net loss $16.9M ($0.32/sh); cash $59.8M; ABI-5366 on track for H1 2024 clinic","bullets":["Net loss $16.9M ($0.32 per share) vs $24.5M ($0.51) in Q2 2022; R&D expense down to $12.5M from $17.8M.","Cash, cash equivalents and marketable securities $59.8M as of June 30, 2023; projected to fund ops through Q3 2024.","Herpesvirus candidate ABI-5366 entered GLP toxicology; IND/CTA submission planned for H1 2024.","Second development candidate nomination expected in 2023; additional candidate to enter clinic by year-end 2024.","Three abstracts accepted for 2023 International HBV Meeting in Kobe, Japan (Sept 19-23)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040590","json":"https://secwatch.observer/filing/0000950170-23-040590.json","markdown":"https://secwatch.observer/filing/0000950170-23-040590.md","text":"https://secwatch.observer/filing/0000950170-23-040590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023040590/0000950170-23-040590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023040590/asmb-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:46:11.677234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bc201224d42b2f96528077d2739fb2f32584223","claim":"ASSEMBLY BIOSCIENCES, INC. reported the quarter ended June 30, 2023 results: net income $16.9 million, or $0.32 per basic and diluted share, EPS $0.32 per basic and diluted share.","evidence_excerpt":"Net loss attributable to common stockholders was $16.9 million, or $0.32 per basic and diluted share, for the three months ended June 30, 2023, compared to $24.5 million, or $0.51 per basic and diluted share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023040590/0000950170-23-040590-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$16.9 million, or $0.32 per basic and diluted share"},{"label":"EPS","value":"$0.32 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}